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Classical scrapie is a prion disease in sheep and goats. In sheep, susceptibility to disease is genetically
influenced by single amino acid substitutions. Genetic breeding programs aimed at enrichment of arginine-171
(171R) prion protein (PrP), the so-called ARR allele, in the sheep population have been demonstrated to be
effective in reducing the occurrence of classical scrapie in the field. Understanding the molecular basis for this
reduced prevalence would serve the assessment of ARR adaptation. The prion formation mechanism and
conversion of PrP from the normal form (PrPC) to the scrapie-associated form (PrPSc) could play a key role
in this process. Therefore, we investigated whether the ARR allele substantially contributes to scrapie prion
formation in naturally infected heterozygous 171Q/R animals. Two methods were applied to brain tissue of
171Q/R heterozygous sheep with natural scrapie to determine the relative amount of the 171R PrP fraction in
PrPres, the proteinase K-resistant PrPSc core. An antibody test differentiating between 171Q and 171R PrP
fragments showed that PrPres was mostly composed of the 171Q allelotype. Furthermore, using a novel tool for
prion research, endoproteinase Lys-C-digested PrPres yielded substantial amounts of a nonglycosylated and a
monoglycosylated PrP fragment comprising codons 114 to 188. Following two-dimensional gel electrophoresis,
only marginal amounts (<9%) of 171R PrPres were detected. Enhanced 171Rres proteolytic susceptibility could
be excluded. Thus, these data support a nearly zero contribution of 171R PrP in PrPres of 171R/Q field
scrapie-infected animals. This is suggestive of a poor adaptation of classical scrapie to this resistance allele
under these natural conditions.
Transmissible spongiform encephalopathies (TSEs) or prion
diseases are infectious neurological diseases for which suscep-
tibility and transmissibility are at least dependent on the strain
of the agent and the prion protein (PrP) genotype of the host,
while other host factors also play a role (3, 6, 13, 18). The
archetypal example is natural scrapie in sheep, for which the
infectious nature was first shown by Cuille´ and Chelle follow-
ing experimental infection of goat and sheep (15). In humans,
various forms of TSEs exist, such as Creutzfeldt-Jakob disease
(CJD), Gerstmann-Stra¨ussler-Scheinker syndrome (GSS), and
kuru (11). The precise nature of the infectious agent is still
uncertain, but it is characterized by the presence of PrP in
misfolded and aggregated forms and named the scrapie form
of PrP (PrPSc) (47). The normal form of the protein is termed
PrPC because of its natural occurrence in cell membranes of
eukaryotic species. Characteristic for PrPSc is its partial resis-
tance to digestion with potent serine endoproteinases such as
proteinase K (PK). While PrPC is fully hydrolyzed by PK, PrPSc
is recovered as PrPres, which consists of prion protein core
fragments that are usually N-terminally cleaved by approxi-
mately 6 kDa. The exact extent of N-terminal cleavage is de-
pendent on strain type-associated conformational conditions
of PrPSc (7, 27, 42, 44, 48).
One of the major features of prion disease susceptibility and
transmissibility is the PrP-related genetic variability of both
host and donor, which, e.g., is evident in sheep (4). The amino
acid sequence of PrP is considered to be conserved between
mammalian species, yet within species it can be polymorphic,
as seen in humans, sheep, and goats, though not typically in
cattle (29, 53, 63, 68). Susceptibility for TSE infection is highly
influenced by single amino acid polymorphisms. In humans,
this has become evident in individuals from Papua New
Guinea who developed genetic resistance for kuru by the evo-
lution of a unique resistance PrP allelotype (codon 127, glycine
to valine [V]) (38). In sheep, variable levels of resistance to
TSEs have been identified and found to be dependent on both
prion strain and PrP polymorphisms. For classical scrapie and
bovine spongiform encephalopathy (BSE) in sheep, three im-
portant amino acid polymorphisms that influence susceptibility
and transmission have been described, i.e., alanine (A) to V at
codon 136, arginine (R) to histidine (H) at codon 154, and
glutamine (Q) to R at codon 171 (3, 28, 29, 57). In atypical/
Nor98 scrapie, a form of scrapie that has poor transmission
properties, susceptibility mainly correlates to a substitution of
R to H at codon 154 or leucine (L) to phenylalanine (F) at
codon 141 (19, 43, 53). Taking the major TSE transmission-
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related polymorphisms of sheep into account, a 3-amino-acid
nomenclature for codons 136, 154, and 171 is used, and
A136R154Q171 (usually indicated ARQ) is considered to be the
wild-type allele. For classical scrapie forms in sheep, the levels
of susceptibility in the context of amino acid substitutions have
been ranked in the following order: VRQ, ARQ, AHQ, and
ARR. Such information has led to successful scrapie eradica-
tion programs in different European countries by use of a
genetic breeding strategy targeted to the enrichment of the
171R allele (23, 40, 62).
A concern of such breeding strategies is whether this type of
genetic selection might lead to the emergence or adaptation of
a new TSE strain that would replicate more efficiently using the
R171 allele. However, for classical scrapie, such a condition
has hardly been reported. It is known that the 171R allele
historically occurs in many breeds at relatively high frequen-
cies, though there is little evidence of scrapie in sheep carrying
this allele. For example, only a small number of scrapie cases
have been associated with ARR/VRQ heterozygous sheep,
while scrapie outbreaks in ARQ/ARR sheep with scrapie are
very rare, and only three natural cases in sheep that are 171R
homozygous have been reported (14, 22, 30, 33). Of significant
importance is whether or not scrapie-positive heterozygous
ARR/VRQ sheep carry equimolar amounts of both PrP alleles
in the PrPSc fraction and if this might be indicative for a
tendency that such cases will lead to enhanced scrapie trans-
missibility within the 171R-carrying sheep population. Thus
far, in the one single ARR/VRQ scrapie field case studied, no
PK-resistant ARR material was detected (41). In vitro studies
already indicate that the binding behaviors of the different PrP
allelic forms to PrPSc are comparable on the molecular level of
PrP (51), while conversion studies have shown that the 171R
allele has a relatively low tendency to become PK resistant (9,
10). After oral BSE challenge of 1- to 2-week-old ARR/ARR
lambs, appreciable levels of ARR PrPSc and PrPres were de-
tected only in the spleen of one out of three asymptomatic
animals euthanized at 10 months after infection (2).
In this study, we determined the involvement of ARR PrP
(further referred to as 171R) in PrPres relative to wild-type
171Q PrP (further referred to as 171Q) in a group of 8 natu-
rally infected sheep with ARR/VRQ scrapie. We used both an
immunochemical discrimination method and a biochemical
separation technique. For the first method, the binding of
monoclonal antibody (MAb) SAF84 to PrP was highly depen-
dent on 171Q-containing allelotypes. The second approach was
a novel technique for the quantitative generation of a 6-kDa
PrP fragment from codons 114 to 188 (114-188PrP) using en-
doproteinase Lys-C digestion of PrPres. Generating this PrP
polypeptide fragment led to detection of differently charged
allelotype polypeptide fragments predicted to be present in
scrapie sheep heterozygous at PrP codon 171. Furthermore, to
compare the resistance of eventual existing 171R PrPres toward
the proteolytic conditions used for these studies, we examined
tissues from 171R/R sheep experimentally infected with clas-
sical BSE and scrapie.
MATERIALS AND METHODS
Chemicals and reagents. Chemicals were purchased from Merck (Darmstadt,
Germany) unless otherwise specified (and were at least analytical reagent grade).
All procedures were performed at room temperature unless otherwise stated.
Purified recombinant ovine PrPs (recPrP) with allelic variants 171R and 171Q
were prepared by a method similar to the method described previously (45, 50).
Endoproteinase Lys-C from Lysobacter enzymogenes was purchased from Sigma
(P2289-3UN). PK was obtained from Merck (30 U/mg; 124568; Merck, Ger-
many). Synthetic peptides with and without an acetylated N terminus and with
amino acid sequences related to the epitope of antibody 6C2 were purchased
from Pepscan Presto (Lelystad, The Netherlands). Gels and reagents for one-
dimensional (1D) and two-dimensional (2D) electrophoresis were purchased
from Invitrogen (Breda, The Netherlands). ImageQuant (version 5.2) Molecular
Dynamics software was from GE Healthcare Life Sciences, Belgium.
Antibodies and epitope mapping. MAbs used were 12B2, 9A2, 1E4, 6C2, L42,
SAF84, and FH6 (16, 25, 26, 33, 52). The epitope specificities of these antibodies
assessed by solid-phase peptide epitope mapping (Pepscan analysis) are 93WG
QGG97, 102WNK104, 102WNKP105, 114HVAGAAA120, 148YEDRYY153,
166YRPVDQY172, and 225SQAYYQ230, respectively. Antibody 1E4 was from
Sanquin BV (Amsterdam, The Netherlands), L42 was from R-Biopharm (Darm-
stadt, Germany), and SAF84 was from Spi-Bio (Massy, France). FH6 is a newly
developed MAb raised by immunization with recombinant ovine 94-233PrP
prepared in Escherichia coli as described previously (67). Immunizations in
PRNP/ 129/Ola mice and monoclonal antibody preparation techniques were
carried out as described previously (24, 37).
Epitope mapping by Pepscan analysis using solid-phase single-amino-acid po-
sition-shifted overlapping 15-mer N-acetylated peptides was performed in min-
iaturized 3-microliter-well cards (20, 56). Further epitope specificity determina-
tions were performed by a blocking enzyme-linked immunosorbent assay
(ELISA). In brief, recPrP was coated on 96-well polystyrene microtiter plates at
0.1 g/ml in 6 M guanidine-HCl in phosphate-buffered saline, pH 7.3. Antibody
6C2 at 6 ng/ml was premixed with epitope 114-120PrP-related peptides in various
concentrations from 10 to 0.0001 g/ml, and the mixture was applied to the
coated wells for 1 h at ambient temperature, washed with 0.05% (wt/vol) Tween
20 in water, and further subjected to 1 h of incubation with rabbit anti-mouse IgG
conjugated to horseradish peroxidase (Dako). Antibody binding was visualized
with 3,3,5,5-tetramethylbenzidine substrate development, and the reaction was
terminated by the addition of 0.7 M H2SO4, before analysis at 450 nm.
Animals and tissues. Tissue samples from sheep with classical scrapie were
obtained from naturally infected flocks following passive and active monitoring
of slaughtered and fallen stock. Some sheep were from the naturally scrapie-
infected Central Veterinary Institute of Wageningen UR (CVI) institutional
flock. Scrapie was confirmed using immunohistochemical (IHC) procedures, as
described for both brain and tonsil tissues (61, 64), and also Western blotting
(WB) techniques (31). PrP genotyping was performed using TaqMan analysis
and pyrosequencing as described before (9, 60).
For evaluating the PK resistance of 171R PrP in PrPres brain stem or thalamus
homogenates, samples of sheep experimentally infected with either BSE or
scrapie were obtained from the Institut National de la Recherche Agronomique
(INRA), Tours and Toulouse, France. All cases showed clinical signs at tissue
collection. The tissues were generated by intracerebral inoculation after different
passages: first-passage BSE from three Poll Dorset ARR/ARR sheep (sheep
PD337, PD368, and PD369, inoculated with bovine BSE), second-passage BSE
from three Suffolk ARQ/ARQ sheep (sheep 1252, 486, and 136, inoculated with
Poll Dorset first-passage ARQ/ARQ BSE), third-passage BSE from two Suffolk
ARQ/ARR sheep (sheep P30 and P130, inoculated with Suffolk second-passage
ARQ/ARQ BSE; thus, it is not an adaptation to the 171R allele during the first
two passages), and classical scrapie from an ARR/ARR sheep from the Langlade
flock. Methods for these studies have been partly published (2).
Tissue treatments. Ten percent (wt/vol) brain stem homogenates were pre-
pared in lysis buffer and digested with PK at 37°C, and PrPres was partially
purified by precipitation with 1-propanol as described previously (31). For PrPres
analyses, pellets were directly subjected to SDS-PAGE and Western blotting.
For further biochemical identification of 171Q and 171R allele fragments,
pellets containing 10 mg tissue equivalents (TEs) were denatured by suspension
in 50 l of 8 M guanidine hydrochloride containing 40 mM dithiothreitol, and
after 5 min at ambient temperature, the protein was precipitated by mixing with
10 volumes of ice-cold (20°C) methanol, kept for 30 min at 20°C, and then
centrifuged at 18,000  g for 20 min at 4°C (5417R; Eppendorf centrifuge). The
final pellet was resuspended in 150 l of 1% (wt/vol) N-lauroylsarcosine sodium
salt in 0.1 M Tris-HCl, pH 8.5, containing 40 mM dithiothreitol, heated for 5 min
at 96°C, and cooled down to ambient temperature. Cleavage of protein at
carboxy-terminal sites of lysines by Lys-C was performed by adding 15 l of a
stock solution of 0.015 U/l of enzyme and incubating at 37°C overnight.
1D electrophoresis (SDS-PAGE). Three volumes of Lys-C-digested sample
were mixed with 1 volume of NuPAGE 4 lithium dodecyl sulfate (LDS) sample
buffer containing 0.1 M dithiothreitol and denatured by heating at 96°C for 5
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min. After cooling to room temperature, the sample was centrifuged at 16,000 
g for 5 min in a Biofuge Pico microcentrifuge. Sample supernatants (10 l, 0.5 mg
TE per lane) were then subjected to 1D electrophoresis in 12% bis-Tris
NuPAGE gels using morpholineethanesulfonic acid (MES) with antioxidant as
running buffer.
2D electrophoresis. The protein in the Lys-C-digested sample (165 l) was
precipitated with 10 volumes of ice-cold (20°C) methanol (without detectable
PrP loss). After consecutive mixing and incubating at 20°C for 30 min, the
sample was centrifuged at 18,000  g (5417R; Eppendorf centrifuge) at 4°C for
20 min. The supernatant was discarded. Further procedures used the supplier’s
(Invitrogen) instructions for 2D electrophoresis. The pellet was resuspended and
diluted into 165 l of sample rehydration buffer (SRB2; 90% [vol/vol] ZOOM
2D protein solubilizer 2, 0.6% [vol/vol] ZOOM carrier ampholytes, pH 3 to 10,
0.002% [wt/vol] bromophenol blue, 0.5% [vol/vol] 2 M dithiothreitol in water).
After centrifugation at 16,000 g for 5 min in a Biofuge Pico microcentrifuge for
debris removal, the supernatant was diluted in SRB2 to obtain 2.5 mg TEs in 140
l per immobilized pH gradient (IPG) strip. ZOOM strips, pH 3 to 10, were
rehydrated with the sample for 1 h in an IPG runner cassette. First-dimension
isoelectric focusing occurred in the IPG runner system with a stepwise voltage
program of from 200 V to 2,000 V for a total run time of 80 min until the dye
front reached the anode. The IPG strips were then equilibrated for the second-
dimension separation by incubation in reducing and denaturing solution for 15
min at ambient temperature according to the supplier’s protocol, followed by
alkylation with iodoacetamide for 15 min. The equilibrated IPG strip was applied
to the NuPAGE Novex bis-Tris ZOOM gel. The reference lane was loaded with
a mixture of 5 l SeeBlue Plus2 marker and 5 l of the 1D SDS-PAGE sample
prepared in the same way described above for the IPG strip to obtain 0.25 mg
TE. Second-dimension electrophoresis was performed for 35 min at 200 V with
MES running buffer and antioxidant.
WB, detection, and quantitation. The subsequent WB procedures—electro-
transfer, immunostaining, and the development of luminescence (using CDP-
Star as the substrate for alkaline phosphatase)—were performed as described
previously (33). Antibodies were used at the concentrations indicated. To obtain
digital images, individual films were exposed to the blots for different time
periods (i.e., 30 s, 1 min, 3 min, and 6 min) and digitalized using a scanner.
Calculations on these digital readings were performed using ImageQuant (ver-
sion 5.2) software. Additional WB studies on PK resistance of PrPres were
performed using a triplex WB system, which uses a recently published fluorimet-
ric method which allows immunochemical quantification of protein without en-
zymatic enhancement (31). Using both Western blot systems, the fractions of R
and Q PrPres present in a typical digest were obtained from the ratios of the
signals obtained with MAbs L42 and SAF84 with L42 binding to both PrP
allelotypes and SAF84 binding only to the 171Q PrP allelotype. These fractions
were calculated as follows: the fraction of the PrP 171Q product in scrapie or
BSE was obtained by applying the formula ratiox/ratioQ/Q where ratiox is the
SAF84/L42 ratio of an unknown sample and ratioQ/Q is the SAF84/L42 ratio
determined for Q/Q homozygous material, which was an average of measure-
ments of at least three different scrapie or BSE 171Q/Q samples; likewise, the
fraction of PrP 171R product could be deduced from the formula (ratioQ/Q 
ratiox)/ratioQ/Q.
RESULTS
Discrimination of R and Q at codon 171 in synthetic PrP
peptides and recombinant PrP using SAF84 binding. The
presence or absence of the allele 171R expression product in
PrPres material from heterozygous (171Q/R) sheep was first
investigated by an antibody discrimination assay. To this end,
the PrP-specific antibody SAF84 was employed since, using
epitope mapping with Pepscan analysis, it appeared to bind the
166YRPVDQY172 sequence containing the 171Q codon (un-
derlined) but not the polymorphic substitution 171R (Fig. 1).
The PrP codon with 171Q specificity for SAF84 binding was
further assessed using an ELISA in which three different re-
combinant PrP variants (ovine VRQ, ARQ, and ARR) were
coated to microtiter plates. The ARR variant (carrying R at
codon 171) exhibited approximately 250 to 1,000 times less
binding to SAF84 than either the VRQ or ARQ allelotype,
whereas antibodies that bound other PrP sites (e.g., MAbs 6C2
and L42) bound all PrP variants equally well (data not shown).
Western blotting, after 1D SDS-PAGE, confirmed the speci-
ficity of SAF84 to 171Q-containing recombinant PrP variants.
RecPrP with the 171R polymorphism (Fig. 2a) showed little or
no binding of SAF84 but showed obvious binding to the 171Q
recPrP variant. The SAF84/L42 binding ratio was less than 0.01
for 171R, while for the 171Q PrP variant a SAF84/L42 ratio of
0.94 was determined. These data confirmed that MAb SAF84
reactivity is specific for the sequence of ovine PrP from codons
166 to 172 with Q at position 171 and that the 171R polymor-
phism does not permit binding. Hence, we concluded that
SAF84 is a suitable antibody to discriminate between PrP car-
rying either an R or a Q at codon 171.
Estimation of 171R/Q-containing allelotype in PrPres from
sheep brain tissue using SAF84. PrPres was prepared from
brain homogenates of scrapie-positive sheep with the ARR/
VRQ, VRQ/VRQ, or ARQ/VRQ genotype. From results with
recPrP, it was assumed that 171Q-dependent SAF84 binding to
PrPres would be less strong if 171R PrPres was present in the
brain homogenates than if only 171Q PrPres was present (com-
pared to a non-polymorphism-dependent MAb like L42). Us-
ing 1D SDS-PAGE followed by Western blotting with MAbs
SAF84 and L42 in parallel, the SAF84/L42 ratios were only
slightly lower in the 171R/Q heterozygotes than the 171Q/Q
homozygotes (0.95  0.08 and 0.99  0.08, respectively),
FIG. 1. Pepscan analysis of antibody SAF84 on overlapping solid-
phase 15-mer peptides of two ovine PrP sequences differing only at
codon 171. (a) Analysis of 171Q PrP; (b) analysis of 171R allelic
variants. With wild-type ovine PrP, this gives 166YRPVDQY172 as the
SAF84 core epitope sequence with 171Q, while there is no binding
observed when the polymorphic amino acid R171 is present. SAF84
was applied at 0.05 g/ml. Of all 220 15-mers, only peptides 151 to 190
are displayed. All other overlapping peptides (data not shown) of the
256 residues of the ovine PrP sequence (21) exhibited background
signals similar to those shown in panel b.
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whereby the differences were not statistically significant (Fig.
2b). If there had been more than 10% of the 171R product
present, the ratio would have been 0.89 (using the 0.99 ratio
in the 171Q/Q sheep as a 100% 171Q reference). Although the
observed ratios were considered equal, if there was any 171R
PrPres present in the brain of 171R/Q heterozygote sheep, it
was calculated that the 171R PrP relative level constituted
4% of the total PrPres material on the basis of these ratio
differences.
Design of a biochemical approach for identification of 171R
and 171Q PrPres in scrapie material. Since the Q-to-R amino
acid change at position 171 involves an obvious charge inver-
sion, we attempted to find potential cleavage fragments of
PrPres that could be measured by 2D analysis. We rationalized,
in principle, that following treatment with the enzyme endo-
proteinase Lys-C (which cleaves after lysine [K] residues), a
75-amino-acid-residue PrP fragment spanning codons 114 to
188 of ovine PrP would be produced. Furthermore, this puta-
tive polypeptide would be of a size sufficiently large to be
studied by gel electrophoresis and Western blotting. The re-
sultant PrP fragment was calculated to have an approximate
molecular mass of 8 kDa and an isoelectric point (pI) of be-
tween 7 and 8 (34). It was also postulated that the PrP frag-
ment, when produced from 171Q- or 171R-containg PrP vari-
ants, would yield a net difference in charge, whereby when
derived from wild-type 171Q PrP, it would have a net ionic
charge of 0, whereas when derived from 171R PrP, it would
carry a net ionic positive charge of 1 (Fig. 3). Thus, the 171R-
containing fragment would have a calculated pI of between 8
and 9 and the two allelic products would differ by about 1 pI
unit and could be readily distinguished using 2D electropho-
resis. Figure 3b suggests also that the 114-188PrP fragment
could potentially carry one asparagine-linked glycosylation site
at codon 184. Following these hypotheses, we optimized ex-
perimental conditions for the preparation, digestion, denatur-
ation, and collection of PrPres fragments from sheep scrapie
brain.
Generation of a 144-188PrP fragment from scrapie brains.
PrPres from scrapie tissue samples was digested with Lys-C and
first resolved by 1D electrophoresis. Subsequent analysis using
Western blotting with antibodies L42 and SAF84 showed the
disappearance of the typical three protein bands correspond-
ing to PrPres and the emergence of smaller polypeptide species
migrating at 6 kDa and at 14 kDa (Fig. 4).These were pre-
sumed to be the nonglycosylated and monoglycosylated forms,
respectively, of the generated 114-188PrP fragment containing
the epitopes of MAbs L42 and SAF84. The epitopes of anti-
bodies 12B2, 9A2, and FH6 were removed, as expected (Fig. 3
FIG. 2. Comparing affinity of PrP-specific antibodies between
171Q and 171R variants of ovine PrP. (a) Western blot of 171R and
171Q recPrPs. The 171Q-dependent MAb SAF84 binds with the 171Q
allele but not with the 171R variant, while reference MAb L42 binds
equally well to both 171Q and 171R recombinant PrP variants. (b)
PrPres material from a scrapie-positive VRQ/VRQ sheep (Q/Q lane)
reacts equally strongly with both MAbs L42 and SAF84. Likewise,
PrPres of scrapie-positive ARR/VRQ sheep (R/Q lane) remained
equally strongly reactive with both L42 and SAF84, yielding nearly
equal SAF84/L42 ratios that were statistically significantly equal by the
two-sided Student t test (P  0.18). For sample loading, 40 and 8 ng
recombinant PrP was applied in the left and right lanes, respectively
(a), and 0.5 mg TE was applied for the scrapie samples (b). Concen-
trations used for L42 and SAF84 antibodies were 0.1 and 0.5 g/ml,
respectively. Arrows indicate molecular mass markers (in kDa). The
SAF84/L42 ratios below the blots are calculated from digitalized film
images of blotting results for eight different 171R/Q cases and eight
different 171Q/Q (2 ARQ/ARQ, 6 ARQ/VRQ) cases.
FIG. 3. Postulated PrPres polypeptide fragment generated by spe-
cific Lys-C cleavage. (a) Mature ovine PrP extending from amino acids
25 to 234. The lysine residues which are cleaved following treatment
with Lys-C are indicated by arrows. (b) Magnified region of the poly-
peptide fragment from codons 114 to 188 obtained after Lys-C cleav-
age of recombinant PrP and scrapie brain-derived PrPres. White ver-
tical bars, 6 basic arginine (R) or lysine (K) residues; black vertical
bars, the 6 acidic glutamic acid (E) and aspartic acid (D) amino acid
residues; bar marked by an arrowhead, the polymorphic 171 codon
that is either a neutral glutamine (Q) or a basic arginine (R). Aspar-
agine at position 184 and 200 can be glycosylated (fork-like structure).
The accumulated charge differences between the Lys-C-generated
fragments are 0 for the 171Q allele and 1 for the 171R allele. The
antibody binding sites for MAbs 12B2, 9A2, 6C2, L42, SAF84, and
FH6 are displayed.
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to 5). The 2-kDa discrepancy between a nonglycosylated 6-kDa
product (shown in Fig. 4) and the 8-kDa product that we
theorized would result from this approach is likely a conse-
quence of the imprecision of the technique for estimating the
molecular masses of proteins with molecular masses below 12
kDa and where the charges of amino acid side chains influence
migration behavior. Unexpectedly, however, the N-terminal
domain of the PrP fragment, which we anticipated to contain
the epitope of the MAb 6C2 (amino acids 114 to 120), was not
present, as illustrated by failure of this antibody to bind the PrP
fragment (Fig. 5a). Since Lys-C cleavage leads to a free amino
terminus, it is conceivable that antibody binding is dependent
on an intact peptide bond at residue 114, the first amino acid
of the 6C2 epitope. Indeed, in a blocking ELISA, the binding
of 6C2 to coated ovine PrP could be prevented by peptides
only if the entire peptide sequence from codons 114 to 120 was
present with an intact peptide bond but not when the 114
residue was terminally present with a free amino terminus (Fig.
5b). This observation, in conjunction with the binding of MAbs
L42 and SAF84 but not 12B2, 9A2, and FH6 and the resultant
6-kDa fragment, collectively indicated that the postulated
cleavage by Lys-C at residues 113K and 188K had occurred to
completion (as opposed to the variable levels of cleavage that
could have occurred at lysines at positions 25, 26, 29, 104, 107,
109, 197, and 207 within PrP).
FIG. 4. Result of Lys-C cleavage displayed in 1D Western blot.
Shown are PK digests of PrPres in seven scrapie isolates from sheep
with either the Q/Q or R/Q genotype at codon 171 before and after
cleavage by Lys-C. Lanes 1 to 6, sample sets from three individual
VRQ/VRQ sheep; lanes 7 to 14, sample sets from four ARR/VRQ
sheep. In each lane, 0.5 mg TE was applied. Lane M, molecular mass
markers (in kDa, arrows). At the right, the positions of the 114-188PrP
fragment with (diamond line) or without (line) a glycosyl group are
indicated. Again, blotting with either SAF84 or L42 yielded nearly
equal staining for all seven sheep, indicative of the minimal presence
of the 171R allele product. Antibody concentrations are as described
in the legend to Fig. 2.
FIG. 5. Evidence for cleavage at lysine residue 113 by Lys-C in
PrPres of ovine scrapie brain material. (a) Electrophoretic pattern of
PrP fragments after cleavage of ovine scrapie material with PK (left
lanes) or PK followed by Lys-C (right lanes) on Western blots immu-
nostained with antibodies L42, 6C2, and FH6. Surprisingly, the band
reactive with L42 at 6 kDa was not reactive with 6C2 (Fig. 3). The
absence of reactivity with C-terminal MAb FH6 at the 6-kDa position
was as expected, and the reactive band below the 6-kDa position could
well be an intermediate digestion product from codons 189 to 234
carrying a glycophosphatidyl anchor. In each lane, 0.5 mg TE was
applied. Concentrations used for L42, 6C2, and FH6 antibodies were
0.1, 0.5, and 0.5 g/ml, respectively. (b) Blocking ELISA to show the
requirement of an N-terminal peptidyl link at lysine 114 of PrP for
MAb 6C2 binding. Peptides with (shaded bars) and without (open
bars) an amino-terminal N-acetyl group differed profoundly in their
affinity only when residue 114 of ovine PrP is the N-terminal residue
(arrows). A high blocking effect corresponds to peptide concentrations
of about or below 0.1 M at 50% blocking. Thus, the presence of the
acetyl group appeared to be essential for 6C2 binding and was consid-
ered representative of an intact peptide bond. For comparison, other
peptide sequences were tested, i.e., the peptide from codons 109 to 122
used for immunization as a positive control (hatched bar) and a pep-
tide set containing the sequence from codons 114 to 123 at the C
terminus, followed by an 8-amino-acid randomized sequence with or
without an N-terminal N-acetyl group (the randomized sequence used
as a control to exclude the influence of C-terminal variations in prox-
imity to the epitope).
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Identification of 171Q- and 171R-containing PrPres frag-
ments after 2D electrophoretic separation. The 114-188PrP
fragment generated by Lys-C treatment of recombinant ovine
171R- and 171Q-containing PrP variants was further charac-
terized using 2D electrophoresis and Western blotting (with
MAb L42). Figure 6a shows that the major cleavage products
from the Lys-C digest migrated as expected, whereby pIs of
approximately 8 for the 171R recPrP-derived polypeptide and
7 for the 171Q-containing recPrP polypeptide were observed.
Also, in 171R recPrP, the pI 8 protein spot showed a positive
reactivity against MAb L42, which was absent when the 171Q-
specific MAb SAF84 was used. This confirmed that the pI 8
spot consisted of 171R protein.
This assay was repeated using PrPres prepared from homozy-
gous 171Q/Q (VRQ/VRQ or ARQ/ARQ) sheep. The diges-
tion products resolved at pIs of 7 and lower for both the
nonglycosylated (6 kDa) and the glycosylated 114-188PrP frag-
ment (14 kDa), but none did so above this pI value (Fig. 6b).
Yet, in five out of eight codon 171 heterozygous (all ARR/
VRQ) cases, 171R 114-188PrP fragment material was margin-
ally evident at pI 8 only at the nonglycosylated 6-kDa migration
position (Fig. 6b, spot above the arrow). This suggests that
171R-containing polypeptide material is of a lower concentra-
tion at pI 8, while nonglycosylated and glycosylated 171Q ma-
terials appeared to be major spots at pI 7 and lower. The pI 8
spot was not detectable in the remainder of the scrapie-in-
fected 171R/Q animals investigated, nor was it detectable in
any 171Q/Q animals (Table 1). In the five cases where a 171R
protein spot was observed, the amount of ARR material in the
pI 8 spot approximated, on average, 2.6% (range, 0 to 8.1%) of
the total protein spots at the glycosylated and nonglycosylated
positions (ARR plus VRQ spots, following densitometric anal-
ysis of digitalized films). These five 171R/Q heterozygous cases
having the pI 8 spot were by 1D analysis among the strongest
positive PrPres cases. In summary, the 171R/Q heterozygous
scrapie-infected sheep investigated did contain the 171R PrP
in their PK-resistant PrPSc material, though at variable con-
centrations and levels below 9% of total PrPres.
Estimation of proteinase K susceptibility of 171R PrPres.
The differential susceptibility of 171R PrPres to PK treatment
FIG. 6. Separation based on charge and molecular mass by 2D
electrophoresis. The 114-188PrP polypeptide fragments generated by
Lys-C cleavage are shown. (a) Result obtained with 171Q and 171R
recPrP applied as a mixture or separately (only Lys-C digestion was
applied); (b) result obtained with VRQ/VRQ and ARR/VRQ scrapie
PrPres (PK and subsequent Lys-C digestion were applied). In panel a,
only the 171R fragment shows a dominant L42-positive protein spot at
pI 8 (arrow) which was not reactive with the 171Q-dependent antibody
SAF84 (data not shown). The reference samples in panels a and b,
shown on the right, contain the respective recombinant PrP and sheep
samples mixed with molecular mass markers and were run only in the
vertical 1D dimension. In panel b, the lines on the right refer to the
6-kDa markers (coinciding with the monoglycosylated 114-188PrPres
fragment), and the lines with diamonds indicate the migration posi-
tions of the glycosylated 114-188PrPres fragment at 14 kDa. Applied
amounts for 1D and 2D analyses were 165 and 330 ng of recombinant
PrP, respectively, in panel a and 0.5 and 2.5 mg TEs of brain stem
tissue, respectively, in panel b. The MAb L42 concentration was 0.1
g/ml. In five out of eight cases, only the ARR/VRQ isolates exhibited
a faint spot at pI 8 (arrow), which was probably also present at the
glycosylated position but too faint for detection due to microhetero-
geneity of sugar chains. Numbers on lines above the panels indicate
isoeletric points.
TABLE 1. Details of sheep scrapie cases analyzed by 2D electrophoresisa
Case code Condition at death Age (mo) Genotype
IHC result
ARR spotb (%)
Tonsil Brain IHC
2004–31 Fallen stock Unk VRQ/VRQ Pos Pos ND
2006–38 Fallen stock Unk VRQ/VRQ Pos Pos ND
621553–4035 Clinical 32.8 ARQ/VRQ Pos Pos ND
573862 Clinical Unk ARR/VRQ Neg Pos ND
2006–25 Fallen stock Unk ARR/VRQ Neg Pos 1.5
2007–19 Fallen stock Unk ARR/VRQ Pos Pos 1
2006–42 Fallen stock Unk ARR/VRQ Neg Pos ND
601677–2861 Found dead 67.2 ARR/VRQ Neg Pos ND
547189–4333 Healthy 81.9 ARR/VRQ Neg Pos 8.1
2004–01 Slaughter Unk ARR/VRQ Neg Pos 6
2007–20 Slaughter Unk ARR/VRQ Wk pos Pos 6
a Cases were either from active surveillance, i.e., those starting with a year number; passive surveillance, i.e., those with a single case number (case 573862); or CVI
institutional flock with circulating natural scrapie (i.e., those with a double case number). Unk, unknown; Pos, positive; Neg, negative; Wk pos, weakly positive; ND,
not determined.
b Polypeptide material in spots at pI 8 was calculated as the percentage of all spots at the 6-kDa and 14-kDa positions, as explained in the Materials and Methods
section. ND, not detected.
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was investigated by applying enzyme concentrations of from 10
to 250 g/ml. In this experiment, not only were field scrapie-
derived materials used, but also materials derived from exper-
imental animals inoculated intracerebrally with scrapie and
BSE. It appeared that in all cases the 171R material was
equally resistant to the protease at concentrations between 10
and 50 g PK/ml and by use of typical experimental conditions
(Fig. 7), notwithstanding 1- to 100-fold variations in PrPres
level between individual samples (see Fig. S1 in the supple-
mental material). For PK concentrations of from 50 to 250 g
PK/ml, there was a 25 to 50% reduction in PrPres signal in the
R allele-containing samples but not in the homozygous
171Q/Q cases of scrapie and BSE. Interestingly, when brain
material from 171R/Q heterozygous sheep experimentally in-
fected with BSE was digested under standard PK conditions of
50 g PK/ml, the amount of 171R-containing PrPres (on the
basis of antibody binding ratios between SAF84 and L42) was
about 64% (standard deviation [SD], 10%). This was much
higher than that for ARR/VRQ field case material from sheep
with classical scrapie, where the 171R-containing fraction rep-
resented less than 9% (Fig. S2 in the supplemental material).
DISCUSSION
An altered form of prion protein is believed to be the major,
if not sole, protein component of the infectious agent in TSE
diseases, and expression of the normal isoform in the host is
essential for disease transmission. Being so critically involved
in disease development, PrP polymorphic sequence variants
genetically determine transmissibility properties, such as the
species barrier, lymphotropism, and within-species susceptibil-
ity, by modulating the interconvertibility of PrP itself. In the
study described in this paper, evidence was found for the pres-
ence of the 171R protein in PrPres from heterozygous ARR/
VRQ scrapie sheep, which usually incubate the disease over 6
years under natural conditions and which carry PrPC of both
the 136V allele, associated with high susceptibility, and the
171R allele, associated with resistance. However, the level of
the 171R protein in PrPres of heterozygous sheep is very low (if
present at all), and in this study, it was quantified to constitute
a maximum of 8.1% of the total PrPres material in such sheep,
contrasting with an expected value of 50% if the expression
level and conversion of both allelic products had been equal in
the tissue of origin. These data were deduced using two inde-
pendent methods: a discriminatory antibody tool and a novel
procedure to generate and separate 114-188PrP fragments
from PrPres containing either the 171Q or 171R codon.
First, the use of MAb SAF84 was chosen because of its
selective affinity to bind ovine PrP containing 171Q, in contrast
to a lack of reactivity for PrP containing the polymorphic
amino acid, 171R. The estimation of the relative amount of the
171R allele in scrapie material obtained using SAF84 was
possible by comparison to that obtained using the nondiscrimi-
native antibody L42, which binds both allelic expression prod-
ucts. The approach of using a polymorphism-dependent PrP-
specific antibody has proven to be a useful way of determining
the genotype status at the codon 171 position in serum of sheep
and for confirming the presence of the 171R allele in PrPres in
spleen and brain of 171R/R homozygous sheep experimentally
challenged with bovine BSE (8). These kinds of estimations
can be safely carried out since the PRNP gene that encodes PrP
is likely expressed equally at the mRNA level for different
genotypes and different cells, even though PrP levels do vary
depending on the tissue (8, 17, 36, 41, 54). Thus, it is assumed
that the different alleles of PrPC studied are present in equal
amounts in brains of healthy heterozygous sheep, yet in
heterozygous ARR/VRQ scrapie-infected individuals, the rel-
ative contributions of the various levels of allele expression
products in the PrPres material are not equal.
The second procedure that we employed is a new tool to
FIG. 7. Resistance to digestion with PK of 171Q and 171R PrPres-
containing ovine brain samples from either scrapie- or BSE-infected
animals shown after Western blotting. Blots were developed using a
triplex WB system. Samples were subjected to three PK concentra-
tions. (a) (Top) Results of classical scrapie of genotypes ARQ/VRQ
532644, ARR/VRQ 2006-42, and ARR/ARR G361 from left to right
(amounts applied, 0.5, 0.5, and 2.5 mg TEs, respectively); (bottom)
results with BSE of genotypes and identity codes ARQ/ARQ 486,
ARQ/ARR P130, and ARR/ARR PD368 from left to right (amounts
applied, 0.5, 0.5, and 1.0 mg TE, respectively). Antibody used was L42
(0.2 g/ml). Bars, 28-kDa molecular mass markers. (b) Overall results
of digestion conditions varying only in applied PK concentrations. The
bars indicate the relative signal to the 50-g PK/ml treatment, pre-
sented where possible as averages  SDs per number (between pa-
rentheses) of sheep analyzed. Sheep genotypes with their identity
codes were ARQ/VRQ 532644, ARQ/ARQ 537272, VRQ/VRQ
553237, ARR/VRQ 2006-42, and experimental ARR/ARR case Lan-
glade G361 for scrapie cases and ARQ/ARQ cases 1252, 486, and 136,
ARQ/ARR cases P30 and P130, and ARR/ARR cases PD337, PD368,
and PD369 for experimental BSE.
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generate a polypeptide core fragment from codons 114 to 188
of ovine PrP from PrPres by using endoproteinase Lys-C diges-
tion. This allowed a clear-cut discrimination of both codon 171
allotypic PrP forms (R/Q) in 2D electrophoresis on the basis of
charge differences. This enzyme has been used before in a
different context for studying the C-terminal fragment carrying
a glycosylphosphatidylinositol anchor (58). In principle, Lys-C
would release the 114-188PrP fragment from PrPs of nearly all
animal species, including humans, the exceptions being some
examples where the C-terminal lysine for cleavage would be
expected to occur at PrP codon 167K (mink) or 197K (felines)
(1, 35, 65). In recombinant PrP as well as proteinase K-treated
scrapie PrPres, the 114-188PrP polypeptide fragment genera-
tion method appeared to be highly selective and sufficiently
robust for the discrimination of 171R/Q-containing ovine PrP
variants under the experimental conditions described. This was
evidenced in the 1D Western blotting analyses, whereby the
nonglycosylated and monoglycosylated PrP fragment forms
were selectively detected using various PrP-specific antibodies;
i.e., the binding of MAb 6C2 appeared to be absent if the
epitope N terminus was processed into a free amino terminus
(as was seen to occur after lysine 113).
Both the selective antibody approach using MAb SAF84/
L42 ratios and the isolation of the 171R fragment by 2D elec-
trophoresis demonstrated that only marginal amounts of the
171R-containing PrP were present (if at all) and constituted
less than 9% of total PrPres. The differential migration at pI 7
and pI 8 of the 6-kDa PrP fragment generated after Lys-C
digestion when using 171Q and 171R recPrP, respectively, was
a consistent indicator that equivalent PrPres fragments were
generated from scrapie brain. We concluded that the involve-
ment of the 171R PrP allele product in PrPres formation is
limited in classical scrapie field cases in ARR/VRQ sheep. The
nature of the additional protein spots at a pI of 7 that were
observed in both recPrP samples and sheep PrPres prepara-
tions is, as yet, unknown and requires further investigation.
Unlike other studies, incomplete processing by PK seems to be
an unlikely explanation since the migration differences in the
second dimension are very small and the ablation of antibody
binding by MAb 6C2 indicates that cleavage at lysine 113 was
efficient. Therefore, it is conceivable that posttranslational dif-
ferences between the additional protein spots are the more
likely explanation. For example, methionine oxidation or
methylated arginines could result in an increase of more acidic
methionine residues or a decrease in the number of basic
arginine residues, which would subsequently affect the overall
net charge and thus explain the differently charged spots at a pI
of 7 (12, 49).
The limited involvement of resistance allele 171R PrP in
PrPSc formed during scrapie infection corroborates the find-
ings observed in in vitro conversion studies with cellular and
recombinant ovine PrPs when sheep are exposed to scrapie or
BSE, in addition to data generated by mass spectrometric
study of a single scrapie-infected ARR/VRQ sheep (9, 10, 32,
41). Our findings that 171R in PrPres was detected in limited
amounts and in only 5 out of 8 ARR/VRQ sheep naturally
infected with classical scrapie indicate that the 171R PrPres is
not always present in PK-resistant material. Alternatively, it
may be present, but at levels less than our current assay limits
will permit detection.
A selective conversion of susceptibility-related 171Q PrPC to
PrPSc in classical sheep scrapie might occur when in heterozy-
gotes a highly susceptible allele, such as a codon 136V PrP, and
a highly resistant allele, such as 171R PrP, are present, as was
suggested before on the basis of in vitro conversion assays with
sheep PrP (9). Similarly, in human heterozygous M/V129 car-
riers with GSS having either the susceptibility mutant codon
198 (Phe 3 Ser) or codon 217 (Gln 3 Arg), this mutant PrP
appeared to be selectively involved in amyloid formation (59).
Other studies on the inherited codon 102L mutant in human
GSS patients (P102L heterozygous) revealed a variable but
minor presence of wild-type PrP of up to 10% of total PrPres
using immunochemical techniques with codon 102-insensitive
and -sensitive PrP-specific antibodies, similar to the method
used here with MAbs L42 and SAF84, respectively (66). How-
ever, in patients either with familial CJD and heterozygous for
the inherited prion disease-related PrP codon 210V/I or with
sporadic CJD with codon 129 M/V, both alleles were equally
present in the proteinase K-resistant prion fraction (55). Our
analysis of experimental BSE samples from sheep with the
ARR/ARQ allele containing up to 65% 171R PrP in PrPres
might indicate either that in this combination both ARQ (wild-
type) and the resistant ARR alleles convert equally well or that
BSE behaves differently from classical scrapie. A difference in
allele composition in PrPres of heterozygotes between infec-
tions in the field and experimental infections might also play a
role, though such information is lacking for sheep. Further-
more, heterozygosity can be a protective factor by itself, as was
shown in cell culture (46).
It seems unlikely that the low/absent levels of the 171R-
containing PrP in PrPres from ARR/VRQ sheep with scrapie
result from the fact that while the 171R allele is converted to
PrPSc, it is more susceptible to proteinase K and therefore
would not be detected. The analysis of samples from a single
ARR/ARR sheep with classical scrapie or sheep with BSE (3
cases studied) did not show differences in susceptibility of
PrPres to proteolytic digestion at the PK concentrations (50 g
PK/ml) used for our studies. At higher concentrations of PK,
however, PrPres 171R allele carriers appeared to be more PK
susceptible than the 171Q/Q homozygotes. In two 171R/R field
cases with classical scrapie, PrPres was shown to be more pro-
tease susceptible than that from 171Q/Q homozygous scrapie
individuals, where higher PK concentrations, at and above 50
g PK/ml, were used (22). A difference in the methodology
used must also be considered, since we used Western blotting
for PrPres detection, which revealed the whole remaining part
of the PrP molecule present in PK-digested PrPSc, while the
study referred to above used an ELISA with octarepeat (56-
88PrP)-specific antibody for PrPres capture. The octarepeat
region might be more prone to removal by PK than the large
region at the C terminus of the octarepeats. Indeed, under our
conditions, such octarepeats can be considered largely re-
moved in both classical scrapie and BSE PrPres from sheep,
while the part of PrP at the C terminus of these repeats re-
mains available for detection (60). Finally, the possibility re-
mains that under certain conditions the infectious entity asso-
ciated with PrP conformations may be protease sensitive.
In the study of Rigter and Bossers, the binding of the 171Q
or 171R allele product to PrPSc appeared to be equal (51).
Therefore, it will be important to understand the mechanisms
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by which PrPC undergoes conversion to its disease-associated
isoform and whether resistance to disease in heterozygotes is a
consequence of poor conversion of a resistance allele (in this
case, 171R PrP) or whether resistance-associated alleles some-
how inhibit the entire process of conversion (including the
conversion of alleles associated with susceptibility to infec-
tion). For other TSEs, including those caused by new and
emerging strains, it is likely that other polymorphisms will play
a more significant role in modulating the conversion process.
For example, it is known that in the atypical/Nor98 scrapie
TSE isolates, the 171R PrP is not a key polymorphism encod-
ing absolute resistance (5). In our study, the methods used
were not appropriate to estimate the level of 171R PrPres in
atypical scrapie material of 171Q/R heterozygotes since, when
using PK, our digestion conditions destroy most of the PrP
region around position 171 eventually present.
Our data, showing the limited presence of 171R PrP in the
PrPSc fraction of infected heterozygous sheep, could imply
that 171R/R sheep infected with classical scrapie have a low
risk of developing a new form of prion disease which has
specifically adapted for this resistance-associated allele. If
there was a significant risk for such adaptation, scrapie or new
forms of TSE in sheep carrying this resistance allele would
likely occur at frequencies much higher than those actually
observed in 171R carriers, given that this allele historically
represents more than 30% of the gene pool in most breeds
(39). For other strains of prion disease, i.e., atypical/Nor98
scrapie or BSE, it is likely that the contributions of allelic PrP
variants other than the sole contribution of the 171R allele in
PrPres formation should be taken into account, though it ap-
pears that atypical/Nor98 scrapie does not transmit under field
conditions and that experimental infection with BSE in 171R
allele carriers is facilitated by intracerebral inoculation and
disease manifests only after long incubation periods (5, 19, 28).
In conclusion, our results strongly support current genetic
breeding programs in sheep aiming at eradication of classical
scrapie with the concurrent potential benefit of preventing
BSE infection.
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